Working Professionals Cohort

Flexible, innovative Master of Science (MS) program will prepare students for excellence in Healthcare Decision Analysis or Biopharmaceutical Marketing.

In an effort to accommodate working professionals who want to accelerate skills and expertise, USC Mann now offers a Working Professionals Cohort (WPC) within the Biopharmaceutical Marketing and the Healthcare Decision Analysis master’s degree programs beginning with the fall 2022 semester.

Designed for flexibility, courses are offered on two weekends and select weeknights. Students have the option to participate from campus, home, the office or even while traveling to meet professional work demands. Courses will incorporate collaborative interdisciplinary team assignments, breakout discussions, and engaging lectures taught by expert faculty and guest lecturers.

To request more information or to apply, contact Michelle Ton, program administrator, at

Olivia Lee

Why did you choose the Healthcare Decision Analysis program?

“The Healthcare Decision Analysis program was recommended to me by a mentor who believed this would be an invaluable career asset to me. As the program was structured with classes on the weekends, I was able to work full-time while obtaining my degree. Upon completion of the program, I have been exposed to more job opportunities and promotions within my field.”

Olivia Lee

MS Healthcare Decision Analysis ’16

Senior Associate Director of Value Evidence and Outcomes, Boehringer Ingelheim
Kevin Ambrose

What inspired you to pursue a master’s in Healthcare Decision Analysis?

“I was drawn to the Healthcare Decision Analysis program because of its focus on the intersection of business, healthcare and pharmaceuticals. I acquired a deep understanding of the healthcare field which has helped me excel in my career in medical affairs. As an added bonus, I was able to easily use my employer’s tuition benefits towards the program.”

Kevin Ambrose

PharmD ’03, MS Healthcare Decision Analysis ’22

Medical Account Director, Novo Nordisk